Iron-deficiency anemia medication
Pro Research Analysisby 
Searched over 200M research papers
Iron-Deficiency Anemia Medication: A Comprehensive Overview
Introduction to Iron-Deficiency Anemia
Iron-deficiency anemia (IDA) is a prevalent condition characterized by a lack of adequate iron to produce hemoglobin, leading to reduced oxygen transport in the blood. It is particularly common among patients with chronic kidney disease (CKD), inflammatory bowel disease (IBD), and pregnant women. Effective treatment is crucial to manage symptoms and improve quality of life.
Intravenous Iron Therapies for CKD
Ferumoxytol
Ferumoxytol is a novel intravenous iron product used to treat IDA in patients with CKD. A Phase III trial demonstrated that ferumoxytol significantly increased hemoglobin levels compared to oral iron, with a mean increase of 0.82 g/dL versus 0.16 g/dL, respectively (P < 0.0001)1. The treatment was well-tolerated, with fewer adverse events compared to oral iron, making it a viable option for rapid iron replenishment in CKD patients1.
Ferric Maltol
Ferric maltol is another oral iron replacement therapy evaluated in CKD patients. A randomized trial showed that ferric maltol significantly increased hemoglobin levels compared to placebo over 16 weeks, with sustained improvements up to 52 weeks6. This therapy was well-tolerated, although gastrointestinal side effects were common6.
Intravenous Iron Therapies for IBD
Ferric Carboxymaltose (FeCarb)
Ferric carboxymaltose has been tested for IDA in IBD patients. A multicenter study found that FeCarb was noninferior to oral ferrous sulfate in increasing hemoglobin levels over 12 weeks, with a faster initial response and better iron store replenishment2. Adverse events were comparable between the two treatments, but FeCarb had a higher rate of early hemoglobin response2.
Iron Sucrose
Iron sucrose has also been compared to oral iron sulfate in IBD patients. A study revealed that both treatments resulted in similar hemoglobin increases, but iron sucrose led to a more significant rise in serum ferritin levels4. Gastrointestinal side effects were less frequent with iron sucrose, suggesting better tolerability4.
Comparative Efficacy of Intravenous Iron Formulations
A systematic review and network meta-analysis compared various intravenous iron formulations for IDA in IBD patients. The analysis highlighted that intravenous iron therapies are generally more effective and better tolerated than oral iron, particularly in patients with severe anemia or intolerance to oral iron compounds8.
Iron Therapy in Pregnancy
Oral iron is commonly used to treat IDA in pregnancy, but it often causes gastrointestinal side effects. Intramuscular and intravenous iron have shown better hematological responses, though concerns about adverse effects like venous thrombosis and allergic reactions persist3. More high-quality trials are needed to assess the clinical outcomes and safety of these treatments in pregnant women3.
Novel Oral Iron Therapies
Ferric Citrate
Ferric citrate is a novel oral iron-repletion agent approved for non-dialysis-dependent CKD patients with IDA. Clinical trials have shown improvements in hemoglobin levels and iron parameters, with good tolerability9. It also serves as a phosphate binder, providing additional benefits for CKD patients9.
Sucrosomial Iron
Sucrosomial iron is another emerging oral iron therapy evaluated in various clinical settings, including CKD. It has shown promise in improving iron parameters with fewer gastrointestinal side effects compared to traditional oral iron supplements9.
Conclusion
The management of iron-deficiency anemia involves a range of therapeutic options, from traditional oral iron supplements to advanced intravenous formulations. Intravenous iron therapies like ferumoxytol, ferric carboxymaltose, and iron sucrose offer rapid and effective iron replenishment, particularly in patients with CKD and IBD. Novel oral iron therapies such as ferric maltol and ferric citrate provide alternative options with improved tolerability. Ongoing research and high-quality clinical trials are essential to optimize treatment strategies and improve patient outcomes in iron-deficiency anemia.
Sources and full results
Most relevant research papers on this topic
Ferumoxytol for treating iron deficiency anemia in CKD.
Ferumoxytol, a novel intravenous iron product, effectively treats iron deficiency anemia in patients with chronic kidney disease, offering a new, efficient option.
RCT
Large Human Trial
Highly CitedA Novel Intravenous Iron Formulation for Treatment of Anemia in Inflammatory Bowel Disease: The Ferric Carboxymaltose (FERINJECT®) Randomized Controlled Trial
Ferric carboxymaltose (FeCarb) is an effective and safe intravenous iron preparation for treating iron deficiency anemia in inflammatory bowel disease patients, providing a fast Hb increase and sufficient iron store refill.
RCTHighly CitedTreatments for iron-deficiency anaemia in pregnancy.
Daily oral iron treatment improves haematological indices in pregnancy but causes frequent gastrointestinal adverse effects, while parenteral iron enhances haematological response but has concerns about potential adverse effects.
Meta-Analysis
Very Rigorous JournalHighly CitedIntravenous Iron Sucrose versus Oral Iron Supplementation for the Treatment of Iron Deficiency Anemia in Patients with Inflammatory Bowel Disease—A Randomized, Controlled, Open-Label, Multicenter Study
Intravenous iron sucrose shows better gastrointestinal tolerability compared to oral iron sulfate for treating iron deficiency anemia in patients with inflammatory bowel disease.
RCTHighly CitedA Phase III, randomized, open-label trial of ferumoxytol compared with iron sucrose for the treatment of iron deficiency anemia in patients with a history of unsatisfactory oral iron therapy
Ferumoxytol is a safe and effective treatment option for iron deficiency anemia in patients unsatisfactory or unable to take oral iron.
RCTLarge Human TrialHighly CitedOral Ferric Maltol for the Treatment of Iron-Deficiency Anemia in Patients With CKD: A Randomized Trial and Open-Label Extension.
Ferric maltol significantly increases hemoglobin and iron indices in patients with chronic kidney disease and iron deficiency, and is well-tolerated for up to 52 weeks.
RCTTreatment efficacy of vitamin C or ascorbate given as co-intervention with iron for anemia - A systematic review and meta-analysis of experimental studies.
Oral vitamin C or ascorbate given with iron does not significantly improve hemoglobin or serum ferritin levels in anemia patients, and future clinical trials are needed to confirm this treatment.
Meta-AnalysisSystematic review with network meta‐analysis: comparative efficacy and tolerability of different intravenous iron formulations for the treatment of iron deficiency anaemia in patients with inflammatory bowel disease
Intravenous iron therapy is recommended for iron deficiency anaemia in inflammatory bowel disease patients with severe anaemia or intolerance to oral iron compounds.
Meta-Analysis
Rigorous JournalHighly CitedNovel Oral Iron Therapies for Iron Deficiency Anemia in Chronic Kidney Disease.
Ferric citrate, a novel oral iron-repletion agent, improves hemoglobin levels and iron parameters in patients with non-dialysis-dependent chronic kidney disease and IDA, with good tolerability.
Individualized treatment for iron-deficiency anemia in adults.
Patients should participate in their care to identify a tolerable daily iron dose and schedule, and follow-up with their physician to implement individualized treatment strategies for iron-deficiency anemia.
Highly Cited